Investor centre

Syncona is a leading FTSE250 company focused on founding, building and funding global leaders in life science

We aim to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

Syncona: 30 September 2020

Net assets


Fully diluted NAV per share


Life science portfolio value


Capital pool supporting investment in life science


Portfolio snapshot

  • 10 portfolio companies in innovative areas of life science
  • 800+ employees across Syncona portfolio
  • 10 live clinical trials across the portfolio